Discussions with leaders: JNM editor-in-chief Johannes Czernin, with Ken Herrmann, continues a series of interviews with leaders in nuclear and molecular imaging and therapy with a conversation with Silke Gillessen, an internationally recognized European oncologist.
Page 169
ComBat harmonization guide: Orlhac and colleagues explain and illustrate with practical examples the use of the ComBat method for harmonization and reduction of imaging “scanner effects” on biomarker values in multicenter studies.
Page 172
Evaluating LATE: Reiger and Silverman offer commentary on the challenges of differential diagnoses of dementia-related proteinopathy disorders, particularly those associated with frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Page 180
T-cell PET imaging toolbox: Li and colleagues provide a state-of-the-art overview of the applications of T-cell PET imaging and its potential to improve clinical management of cancer immunotherapy and T-cell–driven diseases.
Page 183
Thyroid cancer standard of care: Avram and colleagues summarize the essential information needed for multidisciplinary management of differentiated thyroid cancer, emphasizing individualization of 131I therapy based on risk of tumor recurrence.
Page 189
Managing a 131I-MIBG therapy clinic: O’Brien and Pryma discuss the operational aspects of clinical implementation and use of high-specific-activity 131I-MIBG in patients with advanced pheochromocytoma/paraganglioma, including observations from a decade of personal experience.
Page 196
Imaging biomarkers in PDAC: Benz and colleagues assess 18F-FDG PET/CT as an early and late interim imaging biomarker in patients with pancreatic ductal adenocarcinoma who undergo first-line systemic therapy.
Page 199
131I-GD2 scintigraphy before RIT: Zhang and colleagues assess tumor targeting and biodistribution of a 131I-labeled chimeric GD2-antibody clone 14/18 in patients with late-stage neuroblastoma, sarcoma, pheochromocytoma, or neuroendocrine tumors to identify eligibility for radioimmunotherapy.
Page 205
68Ga-FAPI PET/CT in lymphoma: Jin and colleagues profile fibroblast activation proteins in different subtypes of lymphomas and explore the potential utility of 68Ga-FAPI PET/CT in characterizing lesions and extent of disease.
Page 212
177Lu-DOTATATE in lung NETs: Zidan and colleagues report on the efficacy and safety of 177Lu-DOTATATE in patients with somatostatin receptor–positive lung neuroendocrine tumors.
Page 218
Tumor sink effect in PSMA PET: Gafita and colleagues determine in an international, multicenter study the impact of tumor burden on 68Ga–PSMA-11 PET biodistribution using quantitative measurements.
Page 226
aPROMISE standardized PSMA analysis: Nickols and colleagues introduce an automated platform to extend the Prostate Cancer Molecular Imaging Standardized Evaluation criteria in 18F-DCFPyL PET/CT imaging in patients with prostate cancer.
Page 233
PSMA PET/CT IAEA study: Cerci and an international consortium of researchers report on a prospective multicenter study evaluating the diagnostic performance and clinical impact of PSMA-based PET/CT in biochemical recurrence of prostate cancer.
Page 240
EAU BCR risk groups and PSMA PET: Dong and colleagues identify associations between PSMA-targeted PET/CT findings and European Association of Urology–defined risk stratification for biochemical recurrence in prostate cancer.
Page 248
Dose estimation in RLT: Mix and colleagues investigate the value of pretherapeutic kidney function and post-first-cycle dosimetry in predicting cumulative dose at the end of PSMA-based radioligand therapy in prostate cancer.
Page 253
211At-labeled therapy for prostate cancer: Mease and colleagues detail synthesis of and initial preclinical investigations with a new 211At-labeled radiotracer targeting PSMA in prostate cancer.
Page 259
Post-COVID PET/CT in lung disease: Gheysens and colleagues look at current experience and limited data on the value of 18F-FDG PET/CT in COVID-19 lung disease sequelae and preview related articles in this issue of JNM.
Page 268
PET/CT findings after COVID-19: Thornton and colleagues describe experience with the temporal evolution of pulmonary 18F-FDG uptake in patients with COVID-19 and post–COVID-19 lung disease.
Page 270
COVID-19 PET and CT lung changes: Wakfie-Corieh and colleagues explore the potential added diagnostic value of 18F-FDG PET/CT in asymptomatic cancer patients with suspected COVID-19 pneumonia by investigating associations between metabolic and structural changes in lung parenchyma.
Page 274
18F-FDG PET in vasculitis: Dashora and colleagues evaluate the performance of qualitative and semiquantitative scoring methods for 18F-FDG PET assessment in images from patients with large-vessel vasculitis.
Page 280
Hippocampal efAP and tau PET: Raman and colleagues investigate whether early-frame amyloid PET correlates with the presence of tau pathology in a study group of amyloid-positive and -negative patients.
Page 287
Linearization of receptor availability: Khodaii and colleagues determine the accuracy and precision of 3 widely used linearizations of receptor availability (saturation, inhibition, and occupancy plots) in molecular imaging with PET.
Page 294
11C-PiB versus 124I-antibody PET: Meier and colleagues compare an antibody-based PET ligand targeting nonfibrillar amyloid-β with 11C-PiB after β-secretase inhibition in Alzheimer disease mouse models of advanced-stage amyloid-β pathology.
Page 302
68Ga-NODAGA-exendin-4 PET/CT in focal CHI: Boss and colleagues compare the performance of this new radiolabeled exendin-4 tracer with that of 18F-DOPA PET/CT in preoperative detection of focal congenital hyperinsulinism.
Page 310
Standard methods for dose calculations: Stabin and colleagues present standardized methods for collecting data to be used in radiopharmaceutical dose calculations, with steps that can be used as a template for calculating radiation dose estimates from animal or human data.
Page 316
- © 2022 by the Society of Nuclear Medicine and Molecular Imaging.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.